Zions Bancorporation National Association UT Cuts Stake in Zoetis Inc. $ZTS

Zions Bancorporation National Association UT lowered its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 97.8% during the 3rd quarter, Holdings Channel.com reports. The firm owned 692 shares of the company’s stock after selling 30,267 shares during the quarter. Zions Bancorporation National Association UT’s holdings in Zoetis were worth $101,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in the business. Vanguard Group Inc. boosted its position in Zoetis by 1.0% during the third quarter. Vanguard Group Inc. now owns 42,306,764 shares of the company’s stock valued at $6,190,326,000 after buying an additional 419,777 shares during the period. Amica Retiree Medical Trust boosted its holdings in Zoetis by 34.2% during the 3rd quarter. Amica Retiree Medical Trust now owns 2,538 shares of the company’s stock valued at $371,000 after acquiring an additional 647 shares during the period. Phillips Wealth Planners LLC boosted its holdings in Zoetis by 6.1% during the 3rd quarter. Phillips Wealth Planners LLC now owns 2,013 shares of the company’s stock valued at $293,000 after acquiring an additional 115 shares during the period. Amica Mutual Insurance Co. grew its position in Zoetis by 33.7% during the 3rd quarter. Amica Mutual Insurance Co. now owns 28,906 shares of the company’s stock worth $4,229,000 after acquiring an additional 7,293 shares during the last quarter. Finally, Pallas Capital Advisors LLC increased its stake in Zoetis by 24.8% in the 3rd quarter. Pallas Capital Advisors LLC now owns 15,585 shares of the company’s stock worth $2,280,000 after purchasing an additional 3,097 shares during the period. 92.80% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research firms have recently weighed in on ZTS. JPMorgan Chase & Co. dropped their price objective on Zoetis from $230.00 to $200.00 and set an “overweight” rating for the company in a research note on Wednesday, November 5th. The Goldman Sachs Group raised shares of Zoetis to a “buy” rating in a research report on Monday, December 15th. Weiss Ratings lowered shares of Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a report on Wednesday, January 28th. KeyCorp assumed coverage on shares of Zoetis in a research note on Thursday, November 20th. They set a “sector weight” rating for the company. Finally, Morgan Stanley set a $160.00 target price on shares of Zoetis in a report on Thursday, December 18th. Five investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Zoetis has a consensus rating of “Hold” and a consensus price target of $152.91.

Zoetis Trading Up 2.9%

Shares of ZTS opened at $129.17 on Thursday. Zoetis Inc. has a 1-year low of $115.25 and a 1-year high of $177.00. The company has a current ratio of 3.03, a quick ratio of 1.94 and a debt-to-equity ratio of 2.71. The firm’s 50-day moving average price is $125.01 and its 200-day moving average price is $135.02. The firm has a market capitalization of $54.53 billion, a price-to-earnings ratio of 21.46, a PEG ratio of 1.92 and a beta of 0.96.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Thursday, February 12th. The company reported $1.48 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.40 by $0.08. The company had revenue of $2.39 billion during the quarter, compared to the consensus estimate of $2.36 billion. Zoetis had a net margin of 28.24% and a return on equity of 62.02%. Zoetis’s revenue was up 3.0% on a year-over-year basis. During the same period in the prior year, the firm earned $1.40 earnings per share. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. Sell-side analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 2nd. Investors of record on Monday, April 20th will be paid a $0.53 dividend. This represents a $2.12 annualized dividend and a yield of 1.6%. The ex-dividend date of this dividend is Monday, April 20th. Zoetis’s dividend payout ratio is presently 35.22%.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.